Combination therapies for cancer
OwnerHossein A. Ghanbari, Ildiko Csikiinventors
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods for treating cancer by administering to a subject a composition comprising a bacteriophage expressing a fragment of human aspartate β-hydroxylase (ASPH) and an immune checkpoint protein inhibitor.
Claims30
A method for inhibiting growth and/or proliferation of cancer cells in a subject, the method comprising administering to the subject an effective amount of a composition comprising a bacteriophage expressing a fragment of human aspartate β-hydroxylase (ASPH) and an effective amount of an immune checkpoint protein inhibitor.
A method for treating or ameliorating cancer or a symptom of cancer in a subject, the method comprising administering to the subject an effective amount of a composition comprising a bacteriophage expressing a fragment of human ASPH and an effective amount of an immune checkpoint protein inhibitor.
A method for treating or ameliorating cancer or a symptom of cancer in a subject, the method comprising administering to the subject an effective amount of a composition comprising a bacteriophage expressing a fragment of human ASPH and an effective amount of an immune checkpoint protein inhibitor;
- wherein the composition comprising the bacteriophage comprises bacteriophage lambda expressing a fusion protein comprising or consisting of the amino acid sequence of SEQ ID NO:
- 1;
- wherein the composition comprising the bacteriophage is administered at a dose of about 1×1011 particles in a 1 ml intradermal injection every 3 weeks ±3 days for 4 doses then every 6 weeks ±3 days for 6 additional doses, thereafter every 12 weeks ±3 days;
- and
- wherein the immune checkpoint protein inhibitor is pembrolizumab, and wherein the pembrolizumab is administered at a dose of about 200 mg as an intravenous infusion over about 30 minutes every 3 weeks.
A composition comprising:
- a pharmaceutical composition comprising a bacteriophage expressing a fragment of human aspartate β-hydroxylase (ASPH);
- and a pharmaceutical composition comprising an immune checkpoint protein inhibitor;
- wherein said pharmaceutical compositions are in separate containers.
Dependencies are inferred from the claim text.